NineteenGale Therapeutics

NineteenGale Therapeutics is a newly established joint venture by NeuroTheryX Ltd. (NeuroTheryX) and Cyclica, Inc. (Cyclica), aimed at identifying and developing novel cannabinoid-based drugs for bipolar disorder, anxiety, and pain management.Under the initial stealth project, NeuroTheryX combined its phenotype-based drug discovery platform with Cyclica's leading proteome screening platform, Ligand Express, to collaboratively discover new protein targets in the field of neurodegenerative diseases for NeuroTheryX’s lead molecules.